Clinical trials
Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia clinical trials
Below are recruiting relapsed or refractory b-cell acute lymphoblastic leukemia clinical trials, each written for real people, not researchers. We’re tracking 1,758 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07408063RecruitingPhase 2
Study of new drug for advanced head and neck cancer
This trial tests a new drug (GSK5764227) for head and neck cancer that has spread or come back. It looks at your tumor's biomarkers to understand why some people respond to treatment. You may need to have had certain prior treatments depending on which group you join.
Toronto, OntarioAges 18 years+ - NCT07397975Recruiting
Using speech to predict relapse in psychosis
This study uses speech recordings from a smartphone app to see if changes in the way you talk can predict when someone might have a relapse of psychosis. It is for people who are currently stable or for healthy volunteers to compare.
KlecanyAges 18–65 - NCT07389616RecruitingPhase 2/Phase 3
Preventing lymphoma return after transplant
This trial tests a combination of two drugs (cidabenamine and azacitidine) to help prevent peripheral T-cell lymphoma from coming back after a donor stem cell transplant. It is for patients who are at high risk of progression and have already had a transplant.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06453902RecruitingPhase 2
Testing TGRX-678 for advanced CML after prior treatments
This trial tests an experimental drug called TGRX-678 for people with a specific, more advanced stage of chronic myeloid leukemia (CML) called 'accelerated phase.' It’s for patients whose cancer has stopped responding to or who couldn't tolerate earlier targeted therapies (tyrosine kinase inhibitors).
Beijing, Beijing MunicipalityAges 18 years+ - NCT07370207RecruitingPhase 2
Study of AHB-137 for HBeAg negative chronic hepatitis B
This study tests a new medicine called AHB-137 for people with chronic hepatitis B who are HBeAg negative and currently on antiviral therapy. The goal is to see if it can help control the virus better or allow you to stop your current medication safely.
Fitzroy, VictoriaAges 18–65 - NCT07334301RecruitingPhase 1/Phase 2
Combination treatments for relapsed high-risk neuroblastoma
This trial is testing different combinations of medicines for children with high-risk neuroblastoma that has come back. It has two paths: one for children whose disease has relapsed only once, and another for those whose disease has come back more than once. The goal is to find which treatments work best.
SydneyAges 1 year+ - NCT07328425RecruitingPhase 2
A study of lurbinectedin and irinotecan for advanced DSRCT
This trial tests a combination of two chemotherapy drugs (lurbinectedin and irinotecan) for people with desmoplastic small round cell tumor (DSRCT) that has spread or cannot be removed by surgery. It is for patients whose cancer has gotten worse after at least one prior treatment.
Candiolo, TorinoAges 15 years+ - NCT07333118RecruitingEarly Phase 1
Testing GT801 for severe autoimmune diseases
This trial tests a new treatment called GT801, a type of CAR-T cell therapy, for people with moderate to severe autoimmune diseases that have not responded to standard treatments. It aims to see if GT801 can safely and effectively control the disease.
Shanghai, Shanghai MunicipalityAges 18–65 - NCT07321093RecruitingPhase 3
A study of BCD-281 for relapsing-remitting MS
This trial tests a new medicine called BCD-281 for people with relapsing-remitting multiple sclerosis (RRMS). It aims to see if the drug can reduce relapses and improve disease control.
Nizhny NovgorodAges 18–55 - NCT07319897RecruitingPhase 2/Phase 3
BCMA PET scan for multiple myeloma imaging
This trial tests a new type of PET scan that uses a radioactive tracer (68Ga-BCMA) to find active multiple myeloma cells in your body. It may help doctors better detect and monitor the disease.
Beijing, Beijing MunicipalityAges 18–80 - NCT06873100RecruitingPhase 1/Phase 2
Upadacitinib for relapsing polychondritis
This trial tests whether upadacitinib, an oral medication, is safe and effective for people with relapsing polychondritis that hasn't improved enough with standard treatments. It aims to reduce inflammation and control symptoms.
Beijing, Beijing MunicipalityAges 18–70 - NCT07302347RecruitingPhase 1/Phase 2
Study of pembrolizumab for different cancers in Japan
This trial tests a drug called pembrolizumab (Keytruda) to see if it helps people with several types of cancer, including relapsed or refractory lymphoma, melanoma, MSI-high or TMB-high solid tumors, and Merkel cell carcinoma. The goal is to understand if this immunotherapy can shrink or control the cancer.
Nagoya, Aichi-kenAges 6 months+ - NCT07292480Recruiting
Monthly NfL monitoring for relapsing-remitting MS
This trial tests whether monthly blood tests for a nerve protein (NfL) can detect hidden disease activity in people with relapsing-remitting multiple sclerosis (RRMS) who are on certain first-line treatments. It aims to find out if this monitoring helps catch early signs of active disease before symptoms appear.
NiceAges 18–55 - NCT07285889RecruitingPhase 1/Phase 2
Jaktinib as first treatment for acute graft-versus-host disease
This trial tests a new pill called jaktinib for people who develop moderate to severe acute graft-versus-host disease (aGVHD) after a stem cell transplant. The goal is to see if adding jaktinib to standard steroid therapy can better control the disease.
Hangzhou, ZhejiangAges 18 years+ - NCT07271953Recruiting
Help for new moms to stay smoke-free after pregnancy
This trial tests if motivational interviews and a digital game can help women who quit smoking early in pregnancy avoid restarting after giving birth. You will receive support through counseling and a game to stay smoke-free.
Ankara, AnkaraAges 18 years+ - NCT07246096RecruitingEarly Phase 1
CAR-T cell therapy for autoimmune diseases
This trial tests a new CAR-T cell treatment for people with certain autoimmune diseases that have not responded to standard therapies. The treatment uses your own immune cells modified to target and attack disease-causing cells.
ShanghaiAges 18–70 - NCT07236801RecruitingPhase 1
Cell therapy for hard-to-treat autoimmune diseases
This trial tests a new cell therapy called YTS109 for people with several autoimmune diseases that have not improved with standard medications. It aims to see if this treatment can help control the disease when other treatments have failed.
Xuzhou, JiangsuAges 18–65 - NCT07236762RecruitingPhase 1
YTS109 cell therapy for severe autoimmune diseases
This trial tests a new cell therapy called YTS109 for people with severe autoimmune diseases like lupus, Sjögren's syndrome, systemic sclerosis, inflammatory myopathy, vasculitis, and antiphospholipid syndrome. It's for those whose disease hasn't improved with standard treatments.
BengbuAges 18–65 - NCT06909474RecruitingPhase 1
CD5-targeted CAR-NK therapy for relapsed T-cell blood cancers
This trial tests a new therapy using your own immune cells (NK cells) engineered to find and kill cancer cells that carry the CD5 protein. It is for people with T-cell acute lymphoblastic leukemia or certain T-cell lymphomas that have not responded to treatment or have returned.
Wuhan, HubeiAges 18–75 - NCT07228624RecruitingPhase 2
Ruxolitinib before, during, and after transplant for myelofibrosis
This trial tests whether taking the drug ruxolitinib before, during, and after a stem cell transplant helps older patients with myelofibrosis or certain related blood disorders. The goal is to see if this approach can improve transplant success and reduce side effects.
Seattle, WashingtonAges 18–75 - NCT07224152RecruitingPhase 1/Phase 2
NBTXR3 plus radiation for inoperable lung cancer
This trial tests a new drug called NBTXR3, which makes cancer cells more sensitive to radiation. You'll get one injection of NBTXR3 into your lung tumor, followed by standard radiation. It is for people with early-stage non-small cell lung cancer who cannot have surgery.
Houston, TexasAges 18 years+ - NCT07222735RecruitingPhase 1
CAR T cells and radiation for children with sarcoma
This trial tests a combination of targeted radiation and special immune cells (CAR T cells) for children and young adults whose bone or soft tissue sarcoma has come back or not responded to standard treatments. The CAR T cells are made from your own blood cells and are designed to attack a protein called B7-H3 found on the sarcoma cells.
Memphis, TennesseeAges Up to 21 years - NCT07225361RecruitingPhase 4
Ublituximab for early relapsing multiple sclerosis
This study tests ublituximab (Briumvi), a treatment given as an infusion, for people recently diagnosed with relapsing MS. The goal is to see if starting this treatment early helps control MS better.
Chicago, IllinoisAges 18–70 - NCT07220252RecruitingPhase 2/Phase 3
Ublituximab for children with relapsing multiple sclerosis
This trial tests a new drug called ublituximab to see if it can reduce flare-ups in children and teens who have relapsing multiple sclerosis. It aims to understand if the treatment is safe and effective for younger patients.
GdanskAges 10–17
Hear when a new Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory b-cell acute lymphoblastic leukemia?
- Yes. Clin2 currently lists 1,758 recruiting relapsed or refractory b-cell acute lymphoblastic leukemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory b-cell acute lymphoblastic leukemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory b-cell acute lymphoblastic leukemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
- B-cell Acute Lymphoblastic Leukemia
- Relapsed/Refractory Acute Myeloid Leukemia
- Refractory Acute Lymphoblastic Leukemia
- T-cell Acute Lymphoblastic Leukemia
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Relapsed/Refractory B-cell Lymphoma
- Relapsed/Refractory B-cell Malignancies
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.